4 results match your criteria: "Gustave-Roussy Cancer Campus and Paris Sud University[Affiliation]"
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
J Clin Oncol
June 2018
Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after pembrolizumab discontinuation after CR. We describe baseline characteristics and long-term follow-up in patients who experienced CR with pembrolizumab in the KEYNOTE-001 study ( ClinicalTrials.
View Article and Find Full Text PDFHealth-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Eur J Cancer
November 2016
Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Electronic address:
Background: In KEYNOTE-002, pembrolizumab significantly prolonged progression-free survival and was associated with a better safety profile compared with chemotherapy in patients with advanced melanoma that progressed after ipilimumab. We present health-related quality of life (HRQoL) outcomes from KEYNOTE-002.
Methods: Patients were randomly assigned 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or investigator-choice chemotherapy.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
JAMA
April 2016
Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.
Importance: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.
Objective: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma.
Design, Settings, And Participants: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013).
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.
Lancet Oncol
March 2014
Department of Dermatology, University Hospital Essen, Essen, Germany. Electronic address:
Background: Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate for overall survival through a meta-analysis of randomised trials.
Methods: We systematically reviewed randomised trials comparing treatment regimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both PFS and overall survival with a standard hazard ratio (HR).